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ABSTRACT
Objectives: This study aims to measure the private demand
for oral cholera vaccines in Hue, Vietnam, an area of rela-
tively low endemicity of cholera, using the contingent valua-
tion method.
Methods: Interviews were conducted with either the head of
household or spouse in 800 randomly selected households
with children less than 18 years old. Respondents were asked
whether they would purchase an oral cholera vaccine with
different levels of effectiveness and durations of effectiveness
(both for themselves and for other household members) at a
speciﬁed price.
Results: The median respondent willingness to pay for 50%
effective/3-year vaccine was estimated to be approximately
$5, although 17% of the study sample would not pay for a
cholera vaccine. The median economic beneﬁt to a household
of vaccinating all household members against cholera, as
measured by its stated willingness to pay, was estimated to be
$40 for a vaccine with these attributes.
Conclusions: The perceived private economic beneﬁts of a
cholera vaccine were high, but not evenly distributed across
the population. A minority of the people in Hue place no
value on receiving a cholera vaccine.
Keywords: cholera, contingent valuation method, vaccine
demand, willingness to pay.
Introduction
Through a combination of water and sanitation invest-
ments and improved food safety, the threat of cholera
infection has been almost completely eliminated in
industrialized countries. The disease continues to affect
endemic areas in developing countries and causes out-
breaks during ﬂoods, wars, and other natural and
man-made disasters. According to the World Health
Organization (WHO), 52 countries reported cholera in
2005, with a total of 131,943 cases and 2272 deaths
[1]. These estimates understate the scope of the cholera
problem: surveillance is difﬁcult, and many govern-
ments underreport known cases for fear of trade and
travel sanctions.
There is now a new-generation, internationally
licensed vaccine against cholera [2]. This vaccine,
developed in Sweden, is a two-dose killed vaccine con-
sisting of inactivated whole cells of Vibrio cholerae
O1, combined with the B-subunit of the cholera toxin
(BS-WC) [3–5]. This vaccine is safe and can provide
substantial protection against infection. It offers mil-
lions of poor people in developing countries the pos-
sibility of reducing their risk of contracting cholera.
The study reported here explored what this reduced
risk of cholera infection, which a new-generation
vaccine can provide, might be worth to people in the
city of Hue (population 280,000), Thua Thien Hue
Province, Vietnam, from their own perspective.
The average annual incidence of cholera in Vietnam
from 1994 to 2002 has been estimated to be 1.71 cases
per 100,000 inhabitants [6], but that estimate is uncer-
tain. Historically, Thua Thien Hue Province (where
Hue is located) has been one of the high-risk areas for
cholera in Vietnam, with outbreaks in 1980, 1983,
1986, 1990, 1992, 1993, and 2003. The 2003 outbreak
coincided with our ﬁeldwork for this study. During this
2003 outbreak, 50% of cholera cases were in children
less than 18 years old, and the 81 laboratory-conﬁrmed
cases were due to El Tor Inaba V. cholerae O1.
To address the problem of cholera in Vietnam, in
the mid-1980s scientists at the Vietnamese National
Institute of Hygiene and Epidemiology worked with a
research team from the University of Gothenburg in
Sweden to transfer technology for the killed whole-cell
cholera vaccine (without the B-subunit) [7]. This
vaccine was similar but not identical to the oral killed
whole-cell cholera vaccine (without the B-subunit) that
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had been found to confer 50% protection for 3 years
in a randomized, placebo-controlled trial in Bang-
ladesh [3,4].
A two-dose regimen of the locally produced, ﬁrst-
generation Vietnamese vaccine was tested in an open,
controlled ﬁeld trial in Hue in the early 1990s and
was found to confer 66% protection during an out-
break of El Tor Ogawa cholera 8 to 10 months after
vaccination [7]. The duration of protection provided
by the Vietnamese oral cholera vaccine is not known,
but if similar to the Swedish vaccine, it would be
approximately 3 years [4]. Production costs for the
Vietnamese vaccine are low due to the decision not to
include the expensive toxin B-subunit in the vaccine.
The vaccine is delivered pre-emptively from May
through October to children in districts predicted to
have a high incidence of cholera and to all age
groups in areas experiencing an outbreak. In
Vietnam, only a very small proportion of the popu-
lation pays private sector providers for non-
Expanded Program Immunization (EPI) vaccines
against diseases such as rabies, hepatitis B, Japanese
encephalitis, and varicella. These vaccines are gener-
ally not available through the national immunization
program and can only be obtained in a few locations,
typically in large cities.
In 1998, a mass vaccination campaign against
cholera targeting nonpregnant residents more than
2 years of age was conducted in Hue using two doses
of locally produced oral killed bivalent whole-cell
cholera vaccine. The total cost per fully vaccinated
person in 1998 was estimated to be approximately $1,
excluding the costs of foreign expatriate assistance and
the value of time that households spent obtaining the
vaccine [8]. This mass vaccination program provided
an opportunity to assess operational logistics, public
sector costs, and vaccination coverage, but no attempt
was made to estimate the economic beneﬁts of this
cholera vaccine.
In the summer of 2003, we interviewed individuals
in Hue, asking whether they would purchase a (hypo-
thetical) cholera vaccine for themselves and for other
household members if it were available to them at
a speciﬁed price. Each respondent was assigned a
cholera vaccine of certain effectiveness and duration
and a single price; overall the survey design covered
two levels of effectiveness, two levels of duration, and
ﬁve possible prices. The array of responses allowed us
to investigate how private household demand for
cholera vaccines changed with variations in the vaccine
characteristics mentioned earlier. This “stated prefer-
ence” approach, termed the contingent valuation (CV)
method, has been widely used to estimate household
demand for environmental and infrastructure services
in both industrialized and developing countries [9–12].
Researchers have also used CV surveys to estimate
private demand for vaccines that protect against other
diseases, such as malaria [13,14], HIV/AIDS [15,16],
and typhoid fever [17].
The present study was the ﬁrst to use CV methods
to estimate the private economic beneﬁts of a cholera
vaccine. There are a few studies in the literature that
have attempted to estimate the cost-effectiveness of
cholera vaccination interventions in different settings,
but such calculations do not require estimates of
the economic beneﬁts of cholera vaccines [18,19].
Cookson et al. [20] estimated the economic beneﬁts of
cholera vaccines as part of a cost–beneﬁt analysis of a
possible vaccination program in northern Argentina.
They estimated the economic beneﬁts of cholera vac-
cination using medical costs of illness avoided as a
measure of beneﬁts, and reported a cost of illness per
case of $602. This estimate, however, includes very
high managerial costs based on bimonthly transport of
medical personnel to the cholera outbreak areas by
helicopter (some patients were also evacuated by heli-
copter). Their conclusions that cholera vaccination
passes a cost–beneﬁt test cannot be assumed to apply
in South or South-east Asia or Africa, where treatment
costs are much lower.
Our study had three main objectives. The ﬁrst was
to estimate how the price, effectiveness, and duration
of the vaccine would affect individuals’ decisions to
purchase a cholera vaccine for themselves. The second
was to estimate how many vaccines of a speciﬁed
effectiveness, duration, and price an individual would
purchase for other household members. The third was
to estimate individuals’ and households’ willingness to
pay (WTP) for cholera vaccines of different levels of
effectiveness and different durations.
We believe that information about the private
demand for cholera vaccines is important to health
policy decision-makers, even though most govern-
ments in Asia are willing and able to provide free
cholera vaccines to curb major cholera outbreaks.
Cholera infection does not occur only during out-
breaks; endemic cholera remains a problem in many
countries. In Vietnam, cholera is largely episodic, but
these outbreaks occur often. It is thus rational for some
individuals to not want to wait for the government to
declare an emergency before seeking out protection
against infection. The reality is that governments do
not make new-generation cholera vaccines widely
available to individuals who are willing to pay for
them, often on the grounds that there is no private
demand. In this article, we show that private demand
may be signiﬁcant in some places and that individuals
should not necessarily have to wait for the government
to declare an ofﬁcial cholera outbreak before they can
protect their families.
This article presents a summary of our research
methods and ﬁeld procedures, as well as results of our
analysis of the data collected in our CV survey. The
analysis and results address both respondent and
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household demand and WTP. Our closing discussion
reviews the varying degrees of interest in cholera
immunization revealed by our results, and comments
on the general prospects for a user-supported cholera
immunization program in Hue.
Methods
Our research design and ﬁeld procedures for this study
of cholera vaccine demand followed the protocols used
in a companion study of private demand for a typhoid
vaccine, conducted in Hue in 2002 by the same
research team [17]. In this cholera vaccine demand
study, a random sample of 1399 households with chil-
dren aged less than 18 years was selected from six
communes in Hue (ﬁve urban and one semiurban).
Within each household, either the head of household
or spouse was randomly selected to be interviewed;
respondents were required to be less than 65 years of
age. The response rate was 57%. Refusals were very
few, but it proved difﬁcult to ﬁnd and make appoint-
ments with some respondents. Ultimately, 800
in-person interviews were completed.
The research team worked in close collaboration
with both local and foreign public health experts to
develop the CV survey instrument. Three pretests of
the survey instrument were conducted in June 2003 to
reﬁne the language and to determine the set of vaccine
prices to offer. The ﬁnal survey was conducted in
July 2003. The average individual interview took
45 minutes to complete. Each interview proceeded as
follows.
After assessing the respondent’s knowledge and
attitudes about cholera and vaccination, the enumera-
tor provided the respondent with information about
the causes and symptoms of cholera. The concept of
vaccine effectiveness was explained to the respondent
through a technique developed by Suraratdecha et al.
[16]. The respondent’s understanding of the concept of
vaccine effectiveness was then tested. If the respondent
answered the test questions incorrectly, the enumerator
explained the concept again and the respondent was
retested. Regardless of whether the test questions were
answered correctly on the retest, the interview pro-
ceeded. Most respondents (79%) understood the
concept of vaccine effectiveness after it was explained
to them once, and did not need a retest. An additional
12% understood the concept after it was explained a
second time, and passed the retest. The rest of the
respondents (9%) could not grasp the concept of
vaccine effectiveness and failed both the ﬁrst test and
the retest. These respondents tended to be older
women with low education and low income. These
respondents were also more likely to be from semiur-
ban communes.
The enumerator then presented to the respondent a
description of a cholera vaccine. The vaccine described
had been randomly preassigned to that respondent
from an array of four possible types whose attributes
varied in terms of duration and effectiveness. The least
protective hypothetical vaccine was 50% effective for
3 years; the most protective was 99% effective for
20 years. The other two vaccine types (70% effective
for 20 years, 70% effective for 3 years) fell between
those two extremes. (The 50%/3-year vaccine is closest
to the characteristics of the locally produced oral
cholera vaccine in Vietnam.) Each of the four hypo-
thetical vaccine types was available at ﬁve prices:
5,000, 25,000, 50,000, 200,000, and 500,000 Viet-
namese Dong ($0.33, $1.67, $3.33, $13.33, $33.33).
These prices were selected on the basis of pretest
results suggesting that this range included the majority
of the study population’s WTP values for a single
vaccine. The pretest results showed that most people
would agree to pay the lowest price and that almost
everyone would reject the high price.
The enumerator then asked the respondent whether
he or she would choose to purchase the vaccine
described at that price for his or her own immuniza-
tion. Each respondent was asked about only one
vaccine type at a single price. Respondents who
refused to pay the offered price were asked why they
would not pay and whether they would accept the
vaccine for free. Next the respondent was asked how
many vaccines (with these same characteristics and
price) he or she would purchase for other household
members, and for whom in the household these vac-
cines would be purchased.
At the end of the interview the enumerator asked
the respondent how certain he or she was of the
answer given to the vaccine purchase question. A sub-
stantial majority (82%) said they were “very certain”;
only 2% said they were unsure of their answer. Enu-
merators were asked to assess the quality of the inter-
view immediately after completing each survey. Most
of the enumerators (97%) indicated that they believed
that the information they had obtained from the
respondent was reliable.
Five respondents’ interview responses had to be
excluded from our data analysis because their answers
indicated that they thought that the hypothetical
cholera vaccine described to them would not be safe,
even though they had been asked, for our purposes, to
assume that it was safe. Thus, the ﬁnal sample size
available for the analysis was 795.
Statistical Analysis
Because 17% of the sample was out of the market, a
spike model was used to analyze the respondent
demand for the cholera vaccine. The spike model is a
general model for dichotomous choice CV data that
accounts for a mass of observations at zero when
estimating model parameters and calculating WTP
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estimates [21,22]. In contrast to assuming that all
respondents have a positive WTP, the spike model
allows for corner solutions that arise because the
vaccine does not contribute to utility [21]. We estimate
a spike model using parametric maximum likelihood
methods. The spike model uses responses to two ques-
tions: The ﬁrst is whether the respondent is willing to
purchase a vaccine at the given price and then whether
the respondent would take a free vaccine. The second
question is posed only if the response to the ﬁrst is
“no.” If the response to both questions is “no,” the
respondent is assumed to be out of the market and
have zero WTP. Otherwise, the respondent is in the
market. The log likelihood function is
ln ln ln
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where f(·) is the distribution of WTP; d1 is an indicator
that takes the value of 1 if the individual is in the
market (0 otherwise); and d2 takes the value of 1 if the
respondent would pay the vaccine price, pv (0 other-
wise) [21]. In a multivariate context, we assume f(·) is
a function of a vector of individual- and household-
speciﬁc explanatory variables. The mean WTP in this
simple spike model is given by Eq. 2, where X is the
vector of explanatory variables, b is the vector of
parameters estimated by maximizing the likelihood
function, and bp is the estimated parameter for vaccine
price:
− + ( )[ ]1 1β βp Xln exp (2)
Household demand is estimated using a count
model. The simplest count model assumes that the
dependent variable, the number of vaccines the respon-
dent said he would purchase (Ai*), is a random draw
from a Poisson distribution with a mean li. Here li is
a function of a vector of parameters (b) and a vector
of individual- and household-speciﬁc explanatory
variables (Xi). This relationship can be written as
li = exp(Xib), where the exponential speciﬁcation is
used to restrict li to be positive. The probability of
observing household i purchasing Ai*vaccines is
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where ki = 1,2,3 . . . and li = exp(Xib).
Because the respondent would not state that he or
she would purchase more vaccines than there are
people in his or her household, the count data model is
modiﬁed to condition the probability of an observed
outcome on household size. In the modiﬁed model,
which we refer to as the truncated Poisson model, the
probability density function is modiﬁed, so that the
household size is an upper bound for each observation.
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where ki = 1,2, . . . ni
These models yield convenient expressions for
WTP, which is the area under the household demand
curve between zero and n. Assuming the vaccine is
provided for free,
WTP
e
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Results
Socioeconomic and Demographic Characteristics of the
Sample Respondents
Table 1 presents summary statistics of the socioeco-
nomic and demographic characteristics of the 800
respondents in the sample. Most of the households
surveyed were in an urban area. The typical household
had three adults and two or three children. Male and
female respondents were fairly evenly represented; the
average age was about 45 years. Although a modest
majority of respondents (59%) had completed second-
ary school, 26% of respondents reported that they
had difﬁculty reading a newspaper. The average self-
reported monthly household income was $103.
Households were, on average, only 12-minutes
walking distance from the nearest private health facil-
ity and approximately the same distance from the
nearest public Preventive Medicine Center.
Knowledge, Experience, and Risk Perception Regarding
Cholera and Vaccination
A large majority of respondents (90%) reported that
they knew about cholera, and most thought that
cholera is especially serious for children less than
5 years of age and for pregnant women. Compara-
tively few (7%) reported that a household member had
had cholera (33% of those cases were children), and
not very many (11%) claimed to have known someone
personally, other than a household member, who had
been infected with the disease. A much larger number
(50%) thought that one of their children would be
“somewhat” or “very likely” to contract cholera
sometime in the future.
Almost all respondents (94%) knew about vaccines,
but only 58% reported that they had ever been vacci-
nated before, against any disease. Virtually all (98%)
respondents, however, reported that some or all of
their children had received the EPI vaccinations. Not
quite half (43%) of the sample households had at least
one member who had been vaccinated for cholera
during the 1998 or 2000 mass cholera vaccination
campaigns, and 98% of those respondents said they
were “satisﬁed” with the cholera vaccine that had been
122 Kim et al.
received. Approximately half (47%) of the respon-
dents reported that they alone would be primarily
involved in deciding whether other household
members would receive a vaccine; 34% reported that
both the respondent and the spouse would make the
decision together.
Respondent Demand for Cholera Vaccines
Table 2 shows that as the price increases, the percent-
age of respondents who said they would buy the
vaccine declines, for each of the four hypothetical
vaccine types that were offered in our survey. A small
percentage (5–20%) said they would purchase the
cholera vaccine for themselves even at the two highest
prices ($13.33 and $33.33). A substantial number said
they would be unwilling to purchase a cholera vaccine
for themselves at the single (preassigned) price offered.
Of these, some indicated that they would be willing to
accept the vaccine if offered free of charge; others
would not take the vaccine even if offered free of
charge. We classiﬁed all respondents who refused both
the bid and the free vaccine as “out of the market.” In
aggregate, they represent 17% of our total sample.
Most respondents (96%) who said they would pur-
chase a cholera vaccine for themselves stated that they
Table 1 Variable deﬁnition and descriptive statistics
Variable Description Mean (SD)
Demographic and socioeconomic
Respondent’s residence 1 if urban commune; 0 if semiurban commune 0.84
Male respondent 1 if male 0.41
Age of respondent Continuous (in years) 45 (9)
Education edu1 = 1 if never attended school 0.07
edu2 = 1 if completed 1–5 years of school 0.23
edu3 = 1 if completed 6–12 years of school 0.59
edu4 = 1 if university or postgraduate degree 0.11
Household size Number of household members (continuous) 5.4 (1.8)
Household income Monthly household income (continuous, in $) 103 (86)
Water connection 1 if household has own private or shared water connection 0.89
Averting behavior
Washes hands before eating 1 if respondent reported “always” washing hands before eating 0.65
Boils water before drinking 1 if respondent reported “always” boiling drinking water 0.95
Time from house to the nearest private
health facility on foot
Distance from house to the nearest private health facility on foot (in minutes) 12 (10)
Risk
Risk of getting cholera for self 1 if “somewhat likely” or “very likely” that respondent would get cholera
sometime in the future
0.45
Risk of getting cholera for children 1 if “somewhat likely” or “very likely” that children in the household would
get cholera sometime in the future
0.50
Respondent feels cholera is common in his/her
commune
1 if respondent reported cholera is common in his/her commune 0.02
Knowledge and experience
Knows someone who has had cholera 1 if respondent knows someone who has had cholera 0.11
Someone in household has had the oral cholera
vaccine in the past
1 if anyone in the household (including respondent) has had the oral cholera
vaccine in the past
0.43
Efﬁcacy test
Respondent failed vaccine efﬁcacy test twice 1 if failed both rounds 0.09
Vaccine attributes
99% effective/20-year 1 if vaccine is 99% effective for 20 years; 0 otherwise 0.26
70% effective/20-year 1 if vaccine is 70% effective for 20 years; 0 otherwise 0.25
70% effective/3-year 1 if vaccine is 70% effective for 3 years; 0 otherwise 0.24
50% effective/3-year 1 if vaccine is 50% effective for 3 years; 0 otherwise 0.25
Table 2 Percentage of respondents who said they would pur-
chase a cholera vaccine for themselves at the price offered
Price ($) n Yes No % of Yes
99%/20-year
0.33 41 38 3 93
1.67 39 18 21 46
3.33 40 19 21 48
13.33 40 5 35 13
33.33 40 4 36 10
70%/20-year
0.33 39 34 5 87
1.67 40 19 21 48
3.33 40 15 25 38
13.33 40 4 36 10
33.33 40 7 33 18
70%/3-year
0.33 40 32 8 80
1.67 41 18 23 44
3.33 40 16 24 40
13.33 40 5 35 13
33.33 40 3 37 8
50%/3-year
0.33 40 31 9 78
1.67 40 22 18 55
3.33 40 12 28 30
13.33 40 8 32 20
33.33 40 2 38 5
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would do so because they thought the vaccine would
be useful for prevention and safety. Of those who were
unwilling to buy a vaccine at the price offered, 76%
said they would not do so because it was too expensive
or because they had no money. Approximately half
(50%) of those would not accept a vaccine free of
charge said that they did not believe that they had any
chance of becoming infected with cholera. All of these
data suggest that respondents were giving thoughtful,
reasoned answers to the questions posed to them.
The data in Table 2 were used to calculate nonpara-
metric estimates of mean and median respondent WTP
using two different estimators: Turnbull lower-bound
and Kristrom’s midpoint [23]. The WTP results for all
four vaccines for both estimators are presented in
Table 3 for the total sample (second and third
columns) and also only for the respondents who were
“in the market” (restricted sample; ﬁfth and sixth
columns). As expected, the Turnbull lower-bound
WTP estimates are less than the estimates for Kris-
trom’s midpoint estimator, for both the full and the
restricted sample, and the estimates for the full sample
are less than the estimates for the restricted sample, for
both estimators. The nonparametric estimates of mean
respondent WTP ranged from $3.0 for the 70%/20-
year vaccine for the full sample, to $9.2 for the 50%/
3-year vaccine for the restricted sample. Median WTP
estimates ranged from $0.3 to $1.7 for the 70%/3-year
vaccine for the full sample, to $3.3 to $13.3 for the
99%/20-year vaccine for the restricted sample. These
nonparametric estimates suggest that respondent WTP
is insensitive to changes in vaccine effectiveness and
duration [24,25].
Table 4 presents the results for our preferred speci-
ﬁcation of the spike logit model to investigate the
determinants of individuals’ decisions whether to pur-
chase the oral cholera vaccine for themselves at the
price offered. Seven explanatory variables are statis-
tically signiﬁcant and their coefﬁcients have the
expected signs. In the model, respondents are more
willing to purchase a cholera vaccine for themselves
when 1) the price of the vaccine is low; 2) the house-
hold income is high; 3) they have more than
secondary-level education; 4) they are young; 5) they
perceive themselves to be at some risk of getting
cholera in the future; and 6) they know someone who
has been infected with cholera. These results gener-
ally support the construct validity of the respondents’
answers to the CV (WTP) questions. Results for
vaccine effectiveness and duration were, however, not
statistically signiﬁcant, suggesting that respondents
had difﬁculty distinguishing the comparative value of
vaccines with different degrees of effectiveness and
duration [24].
Using the estimated parameters from this spike logit
model, we calculated the mean and median WTP esti-
mates for the four different vaccine types (Table 3).
The mean WTP of the average respondent for a 99%/
20-year cholera vaccine is $7.4, higher than that for
the other three types ($6.3–$6.4). The spike logit esti-
mates of the median WTP ranged from $5.0 for the
50%/3-year vaccine to $6.5 for the 99%/20-year
vaccine. These spike logit WTP estimates are approxi-
mately 20% higher than the lower-bound Turnbull
WTP estimates for the full sample.
Household Demand for Cholera Vaccines
Table 5 presents household demand for cholera vac-
cines in terms of respondents’ willingness to purchase
a vaccine of the preassigned type and price either 1) for
all household members (including the respondent); or
Table 3 Nonparametric and parametric estimates of respondent and household WTP ($) for different cholera vaccines
Vaccine
type
Respondent WTP Household WTP
Full sample (n = 795)
Excluding “out of market”
respondents (n = 650)
Full sample
(n = 795)
Nonparametric Parametric Nonparametric Parametric
Turnbull
lower-
bound
Kristrom
midpoint
Spike
model
Turnbull
lower-
bound
Kristrom
midpoint
Truncated
Poisson
model
99%/20-year
Mean 4.5 7.1 7.4 5.1 8.1 50
Median 0.3–3.3 0.3–1.7 6.5 3.3–13.3 3.3–13.3 49
70%/20-year
Mean 3.0 5.9 6.4 3.8 7.6 46
Median 0.3–1.7 0.3–1.7 5.2 3.3–13.3 3.3–13.3 44
70%/3-year
Mean 4.4 6.6 6.3 5.3 8.2 40
Median 0.3–1.7 0.3–1.7 5.0 1.7–3.3 1.7–3.3 39
50%/3-year
Mean 4.5 6.9 6.3 6.0 9.2 40
Median 1.7–3.3 1.7–3.3 5.0 1.7–3.3 1.7–3.3 37
WTP, willingness to pay.
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2) for none (including the respondent). As shown, at
the lowest price offered ($0.33 per vaccine), a substan-
tial proportion of respondents would purchase a
vaccine for all household members (63% for the 70%/
3-year vaccine; 80% for the 99%/20-year vaccine). At
the highest price ($33.33), very few agreed to purchase
a vaccine of any type for all household members (0%
for the 50%/3-year vaccine; 8% for the 99%/20-year
vaccine). At the lowest price, most respondents (79–
98%) did want to purchase at least one vaccine for
some members of their household. At the highest
prices ($13.33 and $33.33), the majority of respon-
dents (68–85%) said they would not purchase the
vaccine for anyone in their household.
Figure 1 shows how the number of cholera vaccines
an average household would purchase varies with the
price, effectiveness, and duration of the vaccine, on the
basis of a simple tabulation of the survey resultswithout
covariates (for the 634 sample households with fewer
than seven members). At the highest prices ($13.33 and
$33.33), the typical respondent would buy either zero
or one vaccine for the entire household. If the price of
the vaccine were to fall to $3.33 or $1.67, the typical
respondent would purchase about two vaccines (the
average household in this subsample had 4.6members).
At the lowest price ($0.33), the average respondent
would purchase about four vaccines, that is, a vaccine
for almost everyone in the household.
To identify determinants of household demand for
the four cholera vaccine types, we estimated a trun-
cated Poisson model in which the dependent variable is
the total number of vaccines that the respondent
would purchase for the household [14]. As with our
spike logit model of respondent demand, the indepen-
dent variables for household demand describe the
characteristics of the vaccine (price, effectiveness,
duration), the socioeconomic characteristics of the
respondent’s household, and attitudes and perceptions
about cholera and vaccination. The results for our
preferred model speciﬁcation are presented in Table 4.
Table 4 Determinants of respondents’ and household demands for a cholera vaccine (multivariate results)
Independent variable
Respondents’ demand model:
Spike logit model (n = 795)
Household demand model:
Truncated Poisson model
(n = 795)
Coefﬁcient P > z Coefﬁcient P > t
Price of vaccine -0.24 0.00† -0.10 0.00†
Vaccine 99% effective/20-year 0.32 0.14 0.19 0.00†
Vaccine 70% effective/20-year 0.05 0.80 0.05 0.34
Vaccine 70% effective/3-year 0.03 0.88 -0.03 0.56
Resides in urban commune 0.23 0.26 0.35 0.00†
Male respondent -0.04 0.83 0.08 0.05*
Household income 0.01 0.00† 0.003 0.00†
Water connection 0.10 0.69 0.21 0.00†
Boils water -0.15 0.66 -0.32 0.00†
Washes hands before eating -0.01 0.97 0.15 0.00†
Time from house to the nearest private health facility on foot (minutes) 0.00 0.12 0.005 0.00†
Primary education (1–5 years) 0.47 0.13 0.05 0.52
Secondary education (6–12 years) 1.13 0.00† 0.63 0.00†
Completed university 1.04 0.01† 0.90 0.00†
Age of respondent -0.03 0.00† -0.01 0.00†
Respondent feels cholera is common in his/her commune 0.49 0.38 0.07 0.61
Respondent believes it somewhat or very likely that she/he would get cholera
some time in the future.
0.31 0.05* -0.20 0.01*
Respondent believes it somewhat or very likely that children in the household
would get cholera some time in the future.
0.44 0.00†
Knows someone who has had cholera 0.77 0.01† 0.44 0.00†
Someone in household has had the oral cholera vaccine in the past 0.19 0.24 0.12 0.00†
Failed vaccine efﬁcacy test 0.21 0.46 0.09 0.21
Household size -0.03 0.52 -0.01 0.48
Constant 0.76 0.25 0.66 0.00†
Log likelihood -779 -1352
*5% signiﬁcance level, two-tailed test.
†1% signiﬁcance level, two tailed test.
Table 5 Percentage of respondents who would purchase vac-
cines for everyone/no one in the household, by vaccine type and
price
Price 99%/20-year 70%/20-year 70%/3-year 50%/3-year
Would purchase vaccines for all household members
$0.33 80% 64% 63% 67%
$1.67 33% 38% 30% 43%
$3.33 28% 28% 28% 15%
$13.33 10% 8% 5% 15%
$33.33 8% 3% 5% 0%
Would not purchase any vaccines for household members
$0.33 2% 8% 15% 21%
$1.67 31% 40% 45% 30%
$3.33 40% 38% 44% 60%
$13.33 78% 80% 85% 68%
$33.33 83% 80% 83% 85%
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As expected, the price of the vaccine had a negative
and statistically signiﬁcant effect. Demand for the
99%/20-year vaccine was higher than for the other
three vaccine types, a result statistically signiﬁcant at
the 99% level. The results indicate, however, that
respondents did not value the other three vaccines
differently, that is, demand for the 50%/3-year vaccine
was not statistically different from demand for the
70%/3-year vaccine or for the 70%/20-year vaccine.
As with the spike logit model of respondent
demand, all of the key socioeconomic and attitudinal
determinants of vaccine demand in the household
model are statistically signiﬁcant. Household income
and the education of the respondent all have a positive
and statistically signiﬁcant effect on vaccine demand.
Older and male respondents would buy fewer vac-
cines. People living in urban communes would pur-
chase more vaccines than people in semiurban areas.
Respondents who thought that someone in their
household was “somewhat likely” or “very likely” to
contract cholera in the future, and who knew someone
who had had cholera, stated that they would purchase
more vaccines.
The last column in Table 3 reports the mean and
median household WTP estimates from the truncated
Poisson regression models for the four different
vaccine types. These estimates represent the private
economic beneﬁts that would accrue to the average
household if all household members were vaccinated
against cholera free of charge. As anticipated, house-
hold WTP estimates are largest for the 99%/20-year
vaccine (mean $50) and second largest for the 70%/
20-year vaccine (mean $46). Estimates of household
WTP for the 70%/3-year vaccine and the 50%/3-year
vaccine are similar in magnitude (mean $40). The
parameter estimates from this truncated Poisson
regression were used to calculate the average house-
hold WTP for a 50%/3-year cholera vaccine for house-
holds with different characteristics (Table 6). The
mean household WTP is $15 higher among urban
households than semiurban households ($43 vs. $28).
Households in the highest monthly income quartile are
willing to pay about $30 more for vaccines than house-
holds in the lowest household income quartile ($60 vs.
$30). The mean WTP for households with school-aged
children is only $4 higher than that for households
without school-aged children ($41 vs. $37).
Vaccine Coverage versus Vaccine Price
Using these models, we simulated what would happen
if the cholera vaccine were made easily available to
residents of Hue and different prices were charged for
vaccination. Vaccine coverage is slightly higher for the
99%/20-year vaccine than for the other three vaccines.
The model results suggest that approximately half of
the city’s population would choose to be vaccinated
with the 50%/3-year oral cholera vaccine if the two-
dose regime were made available at a price of $1.
These ﬁndings suggest that there is potential for recov-
ering a portion of the costs of a cholera immunization
program from direct user fees. Moreover, 50% cover-
0
5
10
15
20
25
30
35
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5
Number of vaccines
P
ri
ce
 p
er
 v
ac
ci
n
e 
(U
S
$)
50%; 3-year
70%; 3-year
70%; 20-year
99%; 20-year
Figure 1 Average number of cholera vaccines
respondent would purchase for household
members by price of the vaccine (for house-
holds with fewer than seven members; n = 634).
Table 6 Average household WTP ($) for 50%/3-year vaccine,
by household characteristics
Household type n Mean WTP
Urban 665 $43
Semiurban 131 $28
Low-income (1st quartile) 134 $30
Middle-income (2nd and 3rd quartiles) 454 $37
High-income (4th quartile) 208 $60
With school-aged children 796 $41
Without school-aged children 66 $37
WTP, willingness to pay.
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age would probably induce substantial herd immunity
beneﬁts for both the unvaccinated and the vaccinated
individuals [26].
Discussion
Our study suggests that for a household in Hue the
median economic beneﬁt of vaccinating all household
members against cholera, as measured by the house-
hold representative’s (respondent’s) stated WTP, is on
the order of $40 for a vaccine that is 50% effective
with a 3-year duration. These high perceived economic
beneﬁts exist even though most respondents already
have improved water and sanitation services, boil their
drinking water, and have in the past received vaccines
free of charge. The respondents are familiar with vac-
cines and stated that they were quite certain of their
answers to the vaccine purchase questions posed to
them. Demand for a cholera vaccine in Hue, an area of
relatively low endemicity for cholera may have been
inﬂuenced by the small cholera outbreak that occurred
during the course of our ﬁeldwork in the summer of
2003, although we expect this effect was minimal. The
total number of cases in the outbreak was only 81 in a
city of 280,000 people, and very few respondents men-
tioned the outbreak during the interviews.
Respondents’ demand for all four types of the hypo-
thetical cholera vaccine offered in our survey design
was strongly affected by the price of the vaccine. It is
not clear, however, whether respondents answered dif-
ferently depending on which of the four preassigned
vaccine types they were offered. One would hypoth-
esize that at high vaccine prices, respondents who were
offered the 99% effective/20-year (most protective)
vaccine would want to buy more vaccines than respon-
dents who were offered the 50% effective/3-year (least
protective) vaccine. At low vaccine prices, it is unclear
how differences in vaccine type (level of effectiveness
and duration) affected respondents’ willingness to pay
for the vaccine offered. This is because demand for a
vaccine is limited by the size of the respondent’s house-
hold. At the lowest price offered ($0.33 per vaccine), a
majority of respondents would purchase a cholera
vaccine for all household members. If a respondent
wanted to purchase a 70% effective/3-year vaccine
with a price of $0.33 for everyone in the household, we
would not expect them to agree to purchase more
vaccines if they were offered a 99% effective/20-year
vaccine at the same price.
Although the perceived private economic beneﬁts of
a cholera vaccine are high, they are not evenly distrib-
uted across the population. A minority of the people
we interviewed in Hue placed no value on receiving a
cholera vaccine, but a small minority appeared to
value it very highly. A skewed distribution of perceived
private economic beneﬁts is in fact characteristic of
many goods and services, not just vaccines, but it is
inconsistent with the image of the economic beneﬁts of
vaccines that is prevalent among public health profes-
sionals. Because a vaccine has essentially the same
effectiveness and duration for almost all individuals, it
is commonly assumed that the vaccine’s economic ben-
eﬁts to individuals with the same risk of infection
would be similar. The stated preference (CV) results
presented here suggest that similar individuals may
perceive the private economic beneﬁts they would
receive from a cholera vaccine quite differently. Indi-
viduals not only may have different perceptions of the
risk of becoming infected with cholera, but they also
may value the risk reduction offered by a cholera
vaccine differently.
This heterogeneity in preferences for risk reduction
resulted in widely different estimates of the economic
beneﬁts of vaccination across our study population in
Hue. This conclusion must be qualiﬁed, however,
because the skewed distribution of respondent WTP
estimates may have been heavily inﬂuenced by a small
number of respondents who agreed to purchase the
vaccine at the highest prices offered, not because they
wanted the vaccine at that price but because they said
“yes” to please the enumerator in an in-person inter-
view. The mean WTP estimates from CV surveys are
especially sensitive to such yea-saying and enumerator
bias; thus we consider the median WTP estimates to be
more robust and interpretable with greater conﬁdence.
In previous studies, we found that giving respondents
time to think about vaccine purchase decision appears
to be an effective means of reducing yea-saying and
helping respondents give more realistic (lower) esti-
mates of their actual vaccine demand [27]. Because
respondents in this study were not given time to think
about their purchase decisions, we consider the esti-
mates presented here to be upper-bound estimates on
both respondent and household vaccine demand and
WTP.
The uneven distribution of both respondent and
householdWTP estimates across households inHue has
important implications for the design of cholera vacci-
nation programs there and for any attempt to recover
the ﬁnancial costs of vaccine provision. Our results
suggest that there is in fact a signiﬁcant private market
for cholera vaccines in Hue. It appears that if cholera
vaccines were made easily available through private
market channels, a substantial minority of households
would be willing to spend a few US dollars to vaccinate
some of their members. Nevertheless, a mass vaccina-
tion campaign that attempted to recover ﬁnancial costs
would need to charge very low prices to ensure wide-
spread coverage. We estimate that about 17% of the
population has no interest in being vaccinated and
would not pay any amount for a cholera vaccine.
It is important to emphasize that our estimates of
the private economic beneﬁts of a cholera vaccine as
perceived by individuals themselves are an incomplete
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estimate of the economic beneﬁts of a cholera vaccina-
tion program. A large cholera outbreak would not
only paralyze the health-care system, but would also
have serious macroeconomic consequences, particu-
larly in regions where tourism is an important eco-
nomic sector. It is beyond the scope of this research to
estimate the macroeconomic consequences of cholera
outbreaks. Our research is more applicable to cholera-
endemic areas than to situations with large-scale
epidemics.
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